Business Standard

Suven Life Sciences enters asset purchase agreement to buy Rising Pharma

This potential acquisition of Rising's assets would transform Shore Suven Pharma into a strong US generic pharmaceutical company

Suven
Premium

BS Reporter
Suven Life Sciences Limited today announced that it has entered into a 'stalking-horse' asset purchase agreement to buy the assets of Aceto Corporation's Rising Pharmaceuticals and its subsidiaries through its joint venture partner Shore Suven Pharma, Inc., subject to a court-approved bidding process under Section 363 of US Bankruptcy Code.

This potential acquisition of Rising's assets would transform Shore Suven Pharma into a strong US generic pharmaceutical company, according to the company. "Leveraging Rising's extensive product portfolio to become vertically integrated with our already world-class API and finished dose manufacturing capabilities will enable us to better serve US customers," said Suven

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in